RANDOMIZED TRIAL OF BACILLUS CALMETTE‐GUÉRIN (PERCUTANEOUS ADMINISTRATION) AS SURGICAL ADJUVANT IMMUNOTHERAPY FOR PATIENTS WITH STAGE‐II MELANOMA